JANX
Janux Therapeutics, Inc. · Healthcare · Market cap $1.0B
Insiders sold $86K net in the last 90 days ·2 sellers, 0 buyers· latest Form 4 filed Jun 5, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.1M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Aug 1, 2026
Doyle Janeen Noel
Janux Therapeutics, Inc. (JANX) has 22 SEC Form 4 filings (32 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 1, 2026.
Inside the rolling window, 7 insiders at Janux Therapeutics, Inc. reported no open-market purchases and 11 open-market sales totaling $1.1M. The most active filer is Chief Business Officer Meyer Andrew Hollman with 4 filings. The most recent open-market filing is a sale of 4,059 shares by Chief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel, dated Jun 2, 2026, worth $57K.
- Industry:Biotechnology
- CEO:David Alan Campbell
- Employees:108
- HQ:San Diego, CA, US
- IPO:2021-06-11
| Source | |||||||
|---|---|---|---|---|---|---|---|
Doyle Janeen NoelFirst filing | Chief Corp. & Bus. Dev. Ofcr | Sale | 4,059 | $57K | Jun 5 | +26.7% | SEC ↗ |
Dobek MariaFirst in 4 months | Vice President, Accounting | Sale | 2,038 | $29K | May 13 | +15.9% | SEC ↗ |
DiRaimondo ThomasFirst filing | Chief Scientific Officer | Sale | 2,505 | $34K | Jan 2 | +24.0% | SEC ↗ |
Winter Charles M.First filing | Chief Technical Officer | Sale | 2,401 | $33K | Jan 2 | +24.0% | SEC ↗ |
McIver ZachariahFirst filing | Chief Medical Officer | Sale | 2,714 | $37K | Jan 2 | +24.0% | SEC ↗ |
Campbell David AlanFirst filing | President and CEO | Sale | 8,072 | $111K | Jan 2 | +24.0% | SEC ↗ |
Dobek MariaFirst filing | Vice President, Accounting | Sale | 1,462 | $20K | Jan 2 | +24.0% | SEC ↗ |
| Chief Business Officer | Sale | 1,879 | $26K | Jan 2 | +24.0% | SEC ↗ | |
| Chief Business Officer | Sale | 3,333 | $110K | Dec 3 | -1.1% | SEC ↗ | |
| Chief Business Officer | Sale | 3,333 | $100K | Nov 14 | — | SEC ↗ | |
Meyer Andrew HollmanFirst filing | Chief Business Officer | Sale | 16,665 | $501K | Oct 30 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does JANX have?
Janux Therapeutics, Inc. (JANX) has 22 SEC Form 4 filings (32 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Aug 1, 2026.
When was the most recent SEC Form 4 filing for JANX?
The most recent Form 4 filing for JANX on Tracefour is dated Aug 1, 2026.
Who is the most active insider at JANX?
The most active SEC Form 4 filer at JANX in the rolling window is Chief Business Officer Meyer Andrew Hollman, with 4 filings.
What is the net insider flow at JANX over the last 6 months?
Over the trailing 180 days, insiders at JANX have net sold $86K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at JANX in the current window?
Inside the rolling window, insiders at JANX bought $0 and sold $1.1M based on SEC Form 4 filings.
Can I get alerts for JANX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Janux Therapeutics, Inc. (JANX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Janux Therapeutics, Inc. is in the Healthcare sector.